CeriBell, Inc. (NASDAQ:CBLL) Receives Average Recommendation of “Moderate Buy” from Analysts

CeriBell, Inc. (NASDAQ:CBLL) has earned a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $25.1667.

A number of brokerages have commented on CBLL. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research note on Wednesday, October 8th. JPMorgan Chase & Co. decreased their price objective on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Raymond James Financial began coverage on shares of CeriBell in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 target price for the company. TD Cowen decreased their target price on CeriBell from $36.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Finally, BTIG Research reissued a “buy” rating and set a $30.00 price objective on shares of CeriBell in a report on Monday.

CeriBell Price Performance

NASDAQ CBLL traded up $0.61 during trading on Wednesday, reaching $22.60. The company’s stock had a trading volume of 71,017 shares, compared to its average volume of 316,183. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. The firm has a fifty day moving average of $14.71 and a 200 day moving average of $14.56. The stock has a market capitalization of $838.46 million, a PE ratio of -14.91 and a beta of 1.35. CeriBell has a one year low of $10.01 and a one year high of $28.43.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. The firm had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. Analysts expect that CeriBell will post -2.46 EPS for the current fiscal year.

Insider Buying and Selling at CeriBell

In other CeriBell news, Director Josef Parvizi sold 25,000 shares of the company’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $20.26, for a total value of $506,500.00. Following the sale, the director owned 797,652 shares in the company, valued at approximately $16,160,429.52. The trade was a 3.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Xingjuan Chao sold 25,000 shares of the firm’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $18.82, for a total value of $470,500.00. Following the sale, the chief executive officer directly owned 798,135 shares of the company’s stock, valued at approximately $15,020,900.70. This represents a 3.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 202,156 shares of company stock worth $3,483,572 in the last three months. Company insiders own 20.10% of the company’s stock.

Hedge Funds Weigh In On CeriBell

Several hedge funds and other institutional investors have recently modified their holdings of CBLL. Ameritas Investment Partners Inc. boosted its stake in shares of CeriBell by 97.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after buying an additional 1,256 shares in the last quarter. Tower Research Capital LLC TRC increased its position in CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of CeriBell during the third quarter valued at $33,000. Rhumbline Advisers lifted its holdings in shares of CeriBell by 26.5% during the 1st quarter. Rhumbline Advisers now owns 15,629 shares of the company’s stock valued at $300,000 after buying an additional 3,276 shares during the last quarter. Finally, Sei Investments Co. lifted its holdings in shares of CeriBell by 7.1% during the third quarter. Sei Investments Co. now owns 50,454 shares of the company’s stock worth $580,000 after buying an additional 3,365 shares during the last quarter.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.